0 items

in your cart
$0.00

Prescription Drug Search

Product Request Form

Ampyra is currently not available.

Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Ampyra becomes available, please fill out the form below.

Name:
Email:

*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about ExpressMedsCanada.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Ampyra:

  • Anguilla
  • Argentina
  • Armenia
  • Austria
  • Belgium
  • Belize
  • Bolivia
  • Bosnia and Herzegovina
  • Brazil
  • Bulgaria
  • Colombia
  • Costa Rica
  • Cyprus
  • Dominican Republic
  • Ecuador
  • Estonia
  • France
  • Hong Kong
  • Iceland
  • India
  • Iran
  • Korea, Republic of
  • Kuwait
  • Latvia
  • Netherlands Antilles
  • Nicaragua
  • Norway
  • Philippines
  • Poland
  • Qatar
  • Russian Federation
  • Seychelles
  • Singapore
  • Slovakia
  • Sri Lanka
  • Trinidad and Tobago
  • United Kingdom, UK
  • United States, US
  • Uzbekistan
  • Vanuatu
View All Countries

Latest news releases on Ampyra:

UPDATE: Goldman Sachs Initiates Sell on Acorda Therapeutics; Ampyra Risk - Benzinga

Goldman Sachs initiates its coverage on Acorda Therapeutics (NASDAQ: ACOR) with a Sell rating and a price target of $21. Goldman Sachs says, "We view the US market for its key asset Ampyra as largely defined and do not see room for upside to consensus ...

New drug gives Islamorada MS patient freedom of movement - KeysNet

Drug offers new hope In 2010, the Food and Drug Administration approved a new drug made by Acorda Therapeutics based in Hawthorne, N.Y. Ampyra is an extended-release tablet designed to help MS patients with their walking. Meulenberg told her ...

Goldman Sachs Initiates Coverage on Acorda Therapeutics (ACOR) - zolmax.com

The firm set a “sell” rating on the stock. The analysts wrote, “We view the US market for its key asset Ampyra as largely defined and do not see room for upside to consensus estimates, which we would consider necessary to take shares higher.

9 High-Liquidity Mid Caps Poised For Growth - Seekingalpha.com

It manufactures and commercializes VIVITROL for alcohol and opioid dependence; RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA to improve walking in patients with multiple sclerosis ...

Revenues Skyrocket at Merged Alkermes - Analyst Blog - NASDAQ

These schizophrenia drugs are marketed by Johnson & Johnson ( JNJ). Alkermes recorded manufacturing and royalty revenues from Ampyra/Fampyra, marketed for improving walking ability in multiple sclerosis patients, were $13.8 million in the reported quarter.

Goldman Sachs Starts Acorda Therapeutics, Inc. (ACOR) at Sell - StreetInsider.com

The firm said the US market for Ampyra as largely defined and they do not see room for upside to consensus estimates which would be necessary to boost shares. Goldman also said the consensus is underestimating expenses, which could hit the stock.

Revenues Skyrocket at Merged Alkermes - Yahoo Finance

These schizophrenia drugs are marketed by Johnson & Johnson (JNJ). Alkermes recorded manufacturing and royalty revenues from Ampyra/Fampyra, marketed for improving walking ability in multiple sclerosis patients, were $13.8 million in the reported quarter.

6 High-Growth Biotechnology Stocks With Great Liquidity - Seekingalpha.com

Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Alkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013 - PharmiWeb

Manufacturing and royalty revenues from AMPYRA®/FAMPYRA®1 were $24.6 million for fiscal 2012. Alkermes, Inc. did not record any revenues for AMPYRA/FAMPYRA for fiscal 2011. Net sales of VIVITROL® were $41.2 million for fiscal 2012, compared to $28.9 ...

Customer Service
1-866-799-3435 - Use Discount Code 7500 | Contact Form
Copyright © 2012 ExpressMedsCanada.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK